On Tuesday, Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)’s shares declined -1.99% to $2.95.
Sunesis Pharmaceuticals, Inc. (SNSS) was making moves as the week drew to a close. This company was part of the red-hot health care sector, but it really did not gain any benefit from it. Back in September, Sunesis went from being a $6 stock to a $2 stock. However in Friday’s session this stock is making a comeback.
Friday morning, the company declared additional results of its VALOR trial, a Phase 3 study of vosaroxin and cytarabine in adult patients with relapsed or refractory acute myeloid leukemia (AML).
Basically, VALOR is a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 711 adult patients with first relapsed or refractory AML at 124 leading sites in 15 countries. Detailed results of the VALOR trial were presented in the “Late Breaking Abstracts” session of the American Society of Hematology (ASH) Annual Meeting in December 2014.
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has accomplished a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML.
Depomed Inc (NASDAQ:DEPO)’s shares dropped -1.62% to $23.08.
Depomed Inc (DEPO) declared it has reached a settlement agreement in its ongoing patent litigation related to an Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Depomed’s Zipsor® (diclofenac liquid filled capsules) 25mg tablets. The settlement permits defendant Watson Laboratories Inc. to start selling generic Zipsor on March 24, 2022, or earlier under certain circumstances. The settlement concludes all ongoing ANDA litigation related to Zipsor.
The settlement agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the U.S. District Court for the District of New Jersey.
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the administration of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.
At the end of Tuesday’s trade, Alaska Air Group, Inc. (NYSE:ALK)‘s shares surged 0.45% to $66.52.
SkyWest Airlines declared that they will purchase eight new, dual-class Embraer E175 jets to fly for Alaska Airlines. The new planes, to be delivered in 2016, will replace eight older regional jets SkyWest presently flies for the Seattle-based carrier.
The declarement comes the same month SkyWest takes ownership of the first of seven E175s purchased last fall to be flown for Alaska under a capacity purchase agreement (CPA). The regional carrier will start flying the planes for Alaska on July 1 with the start of new service from Seattle to both Milwaukee and Oklahoma City, and between Portland, Oregon and St. Louis.
Alaska Air Group, Inc., through its auxiliaries, provides passengers and cargo air transportation services primarily in the United States. The company operates through Alaska Mainline and Alaska Regional segments. It serves about 100 cities in Alaska, the Lower 48, Hawaii, Canada, and Mexico. As of December 31, 2014, the company’s fleet comprised of 137 Boeing 737 jet aircraft; and 51 Bombardier Q400 turboprop aircraft. The company was founded in 1932 and is based in Seattle, Washington.
First Solar, Inc. (NASDAQ:FSLR), ended its Tuesday’s trading session with 0.74% gain, and closed at $51.49.
First Solar, Inc. ( FSLR) declared that it has signed an agreement to supply its high performance photovoltaic (PV) modules to power the 200 megawatt (MW)AC second phase of the Mohammed bin Rashid Al Maktoum Solar Park in Dubai, the United Arab Emirates.
Earlier this year, a consortium led by ACWA Power, a leading water and power developer, owner and operator based in Saudi Arabia, and TSK, a Spanish engineering and construction company, was selected by the Dubai Electricity and Water Authority (DEWA) to develop, construct, own and operate the independent power project. According to the consortium, the project’s tariff of 5.84 USD cents per kilowatt-hour establishes a new global benchmark, reducing the cost of solar electricity by over 20 percent.
Significantly, the utility scale solar plant will be the largest facility of its kind in the Middle East when accomplished in early 2017. The plant will produce enough energy to power 30,000 average homes in the UAE and will displace over 469,650 metric tons of carbon dioxide per year. The project will be powered by over 2.36 million First Solar modules, contrast to the 152,880 that were installed in the 13MWAC first phase of the Mohammed bin Rashid Al Maktoum Solar Park. The plant will be built over an area of almost 4.5 million square meters, sufficient to cover as many as 100 soccer pitches.
First Solar, Inc. provides solar energy solutions worldwide. The company operates through two segments, Components and Systems. The Components segment designs, manufactures, and sells solar modules that convert sunlight into electricity. This segment manufactures cadmium telluride and crystalline silicon modules for project developers and system integrators, in addition to owners and operators of photovoltaic (PV) solar power systems.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
